Z
Zuzana Kos
Researcher at University of Toronto
Publications - 9
Citations - 2175
Zuzana Kos is an academic researcher from University of Toronto. The author has contributed to research in topics: Breast cancer & Medicine. The author has an hindex of 3, co-authored 3 publications receiving 1566 citations. Previous affiliations of Zuzana Kos include Ottawa Hospital & University of Ottawa.
Papers
More filters
Journal ArticleDOI
The evaluation of tumor-infiltrating lymphocytes (TILs) in breast cancer: recommendations by an International TILs Working Group 2014
Roberto Salgado,Carsten Denkert,Sandra Demaria,Nicolas Sirtaine,Frederick Klauschen,Giancarlo Pruneri,Stephan Wienert,G. Van den Eynden,Frederick L. Baehner,Frédérique Penault-Llorca,E. A. Perez,E. A. Thompson,William Fraser Symmans,Andrea L. Richardson,Jane E. Brock,Carmen Criscitiello,Helen Bailey,Michail Ignatiadis,Giuseppe Floris,Joseph A. Sparano,Zuzana Kos,Torsten O. Nielsen,David L. Rimm,Kimberly H. Allison,Jorge S. Reis-Filho,Sibylle Loibl,Christos Sotiriou,Giuseppe Viale,Sunil S. Badve,Sylvia Adams,Karen Willard-Gallo,Sherene Loi +31 more
TL;DR: Current data on the clinical validity and utility of TILs in BC are reviewed in an effort to foster better knowledge and insight in this rapidly evolving field, and to develop a standardized methodology for visual assessment on H&E sections.
Journal ArticleDOI
Prognostic significance of FOXP3+ tumor-infiltrating lymphocytes in breast cancer depends on estrogen receptor and human epidermal growth factor receptor-2 expression status and concurrent cytotoxic T-cell infiltration
Shuzhen Liu,William D. Foulkes,William D. Foulkes,Samuel Leung,Dongxia Gao,Sherman Lau,Zuzana Kos,Zuzana Kos,Zuzana Kos,Torsten O. Nielsen +9 more
TL;DR: FOXP3+ regulatory TILs are a poor prognostic indicator in ER+ breast cancer, but a favorable prognostic factor in the HER2+/ER+ subtype.
Journal ArticleDOI
Systematically higher Ki67 scores on core biopsy samples compared to corresponding resection specimen in breast cancer: a multi-operator and multi-institutional study
Kelley M. Kidwell,Indu Arun,Sunil Badve,Anita Bane,John M. S. Bartlett,Jane Bayani,Henk J. Buikema,Martin C. Chang,Robin L. Dietz,Susan Fineberg,Cornelia M Focke,Dongxia Gao,Allen M. Gown,Carolina Gutierrez,Johan Hartman,Anne Vibeke Lænkholm,Arvydas Laurinavicius,Richard M. Levenson,R. Mahboubi-Ardakani,Sharon Nofech-Mozes,C. Kent Osborne,Mary Anne Quintayo,Tilman T. Rau,Stephanie Robertson,Roberto Salgado,Tomoharu Sugie,Giuseppe Viale,Lila Zabaglo,Mitch Dowsett,Torsten O. Nielsen,David L. Rimm,Daniel F. Hayes,Lisa M. McShane,Samuel Leung,Balazs Acs,Yalai Bai,Annika Blank,Signe Borgquist,Angela Chan,Carsten Denkert,Andrew Dodson,Anna Ehinger,Matthew J. Ellis,Margaret Flowers,Chad D. Galderisi,Abhi Gholap,Douglas J. Hartman,Judith Hugh,Anagha P. Jadhav,Elizabeth N. Kornaga,Zuzana Kos,Hans Kreipe,Takuya Moriya,Hongchao Pan,Liron Pantanowitz,Ernesta Paola Neri,Frédérique Penault-Llorca,Mei Yin C. Polley,Tammy Piper,Stefan Reinhard,Jason Ruan,Takashi Sakatani,Lois E. Shepherd,Ian E. Smith,Joseph A. Sparano,Melanie Spears,Malini Srinivasan,Jane Starczynski,Austin Todd,B. van der Vegt,Shakeel Virk,Ying Wang,Hua Yang,Zhiwei Zhang,Inti Zlobec +74 more
TL;DR: In this paper , an automated digital image analysis (DIA) platform was used to evaluate tumoral Ki67 expression in breast cancer patients using a set of 60 previously stained slides containing 30 core-cut biopsy and 30 corresponding resection specimens.
Journal ArticleDOI
Developing a new generation of breast cancer clinical gene expression tests.
Zuzana Kos,Torsten O. Nielsen +1 more
TL;DR: The authors confirm the assay’s independent prognostic value in premenopausal and postmenopausal, node-positive women treated with contemporary chemotherapy followed by endocrine therapy; EndoPredict did not, however, predict benefit from adding paclitaxel.
Journal ArticleDOI
Abstract P4-02-16: Prognostic and Predictive Capacity of Tumor Infiltrating Lymphocytes in the MA.20 regional radiotherapy trial
Nazia Riaz,Bingshu E. Chen,Anita Bane,Dongxia Gao,Elisabeth Specht Stovgaard,Zuzana Kos,Samuel Leung,Elahe Shenasa,Wendy R. Parulekar,Shelley Chambers,T. O. Nielson,Timothy J. Whelan +11 more
TL;DR: In this paper , the benefit of regional nodal irradiation (RNI) in patients with low burden metastatic axillary disease (MA) was established in MA, where patients randomized to receive adjuvant whole breast irradiation plus RNI experienced a significantly better disease free survival (DFS) compared to those who received WBI alone and this advantage was maintained in the hormone receptor negative subgroup.